These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3892706)

  • 41. Complications of cytostatic therapy in childhood leukemia.
    Thunold S; Moe PJ
    Acta Pathol Microbiol Scand Suppl; 1973; 236():84-96. PubMed ID: 4521321
    [No Abstract]   [Full Text] [Related]  

  • 42. [Bone marrow changes in acute non-lymphocytic leukemia patients treated with low-dose Ara-C--implications of therapeutic mechanism].
    Lin SF; Liu HW; Chen JR; Chien CH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Sep; 3(9):612-7. PubMed ID: 3483023
    [No Abstract]   [Full Text] [Related]  

  • 43. [Arabinosilcytosine in the treatment of acute leukemia (author's transl)].
    Pozzi D; Mori NS; Jamra M
    Rev Bras Pesqui Med Biol; 1974; 7(1):13-8. PubMed ID: 4532776
    [No Abstract]   [Full Text] [Related]  

  • 44. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells.
    Chou TC; Arlin Z; Clarkson BD; Phillips FS
    Cancer Res; 1977 Oct; 37(10):3561-70. PubMed ID: 332337
    [No Abstract]   [Full Text] [Related]  

  • 45. 5'-(3')-nucleotidase mRNA levels in blast cells are a prognostic factor in acute myeloid leukemia patients treated with cytarabine.
    Galmarini CM; Cros E; Graham K; Thomas X; Mackey JR; Dumontet C
    Haematologica; 2004 May; 89(5):617-9. PubMed ID: 15136231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
    Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
    Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of tetrahydrouridine on the uptake and metabolism of 1-beta-D-arabinofuranosylcytosine in human normal and leukemic cells.
    Ho DH; Carter CJ; Brown NS; Hester J; McCredie K; Benjamin RS; Freireich EJ; Bodey GP
    Cancer Res; 1980 Jul; 40(7):2444-6. PubMed ID: 6248205
    [No Abstract]   [Full Text] [Related]  

  • 48. Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.
    Mayer RJ; Schiffer CA; Peterson BA; Silver RT; Cornwell GG; McIntyre OR; Rai KR; Budman DR; Ellison RR; Maguire M
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):84-90. PubMed ID: 4012343
    [No Abstract]   [Full Text] [Related]  

  • 49. Low-dose cytarabine: chromosomal findings suggesting its cytostatic as well as differentiating effect.
    Hossfeld DK; Weh HJ; Kleeberg UR
    Leuk Res; 1985; 9(2):329-30. PubMed ID: 3990338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multidrug resistance expression and proliferative studies in poor risk acute myeloid leukemia treated with the FLAG (G-CSF plus fludarabine and Ara-C) regimen.
    Tafuri A; De Felice L; Petrucci MT; Mascolo MG; Ricciardi MR; Ciliberti C; Martelli MP; Petti MC
    Cytokines Mol Ther; 1995 Dec; 1(4):301-7. PubMed ID: 9384683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cytokinetic changes in the peripheral blood of leukemic patients during cytostatic therapy. VI. Effect of arabinosylcytosine.
    Montecucco CM; Riccardi A; Cresci R; Mazzini G; Ascari E
    Basic Appl Histochem; 1980; 24(4):423-34. PubMed ID: 6934771
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia.
    Riddell S; Appelbaum FR; Buckner CD; Stewart P; Clift R; Sanders J; Storb R; Sullivan K; Thomas ED
    J Clin Oncol; 1988 Apr; 6(4):576-82. PubMed ID: 3282031
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A simultaneous study of bone marrow, spleen, and liver in chronic myeloid leukemia: evidence for differences in cell composition and karyotypes.
    Baccarani M; Zaccaria A; Santucci AM; Bagnara GP; Ricci P; Gobbi M; Ruggero D; Brunelli MA; Tura S
    Ser Haematol; 1975; 8(4):81-112. PubMed ID: 1071286
    [No Abstract]   [Full Text] [Related]  

  • 54. Correlation of response to 1-beta-D-arabinofuranosyl cytosine and metabolism of drug by tumor.
    Gailani S; Nussbaum A
    J Med; 1976; 7(2):93-102. PubMed ID: 1064685
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Results of high-dose cytarabine therapy. A review].
    Gassmann W; Schmitz N; Löffler H
    Onkologie; 1985 Feb; 8(1):8-15. PubMed ID: 3885125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cell kinetics and practical consequences for therapy of acute leukemia.
    Bleich HL; Boro ES
    N Engl J Med; 1975 Aug; 293(8):389-93. PubMed ID: 1057045
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
    Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
    Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Latent period of 9 years in the presentation of a myeloproliferative disorder.
    Watkins SM; Williams JR; Turnbull AL
    Scand J Haematol; 1983 Sep; 31(3):280-2. PubMed ID: 6576465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical effect of low dose ara-C in twenty patients with acute nonlymphocytic leukemia, atypical leukemia, and refractory anemia with excess of blasts.
    Izumi Y; Sawada H; Okazaki T; Mochizuki T; Ishikura H; Tashima M; Yamagishi M; Uchino H; Usui T; Akasaka S
    Nihon Ketsueki Gakkai Zasshi; 1986 Feb; 49(1):93-100. PubMed ID: 3705895
    [No Abstract]   [Full Text] [Related]  

  • 60. [Experiences in the treatment of immature cell leukemias with cytosine arabinoside and daunorubidomycin].
    Schmalzl F; Braunsteiner H
    Wien Klin Wochenschr; 1971 Jun; 83(25):452-6. PubMed ID: 5289111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.